Physician profile
Prathima Prodduturi
NPI 1356505473
$4,530.89
in general payments reported to CMS, 2019-2025
31 companies · $677 in 2025
The $677 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $203 · 2021: $264 · 2022: $613 · 2023: $305 · 2024: $1,753 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472 · Consulting Fee: $1,138 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.20 |
| Consulting Fee | $1,137.50 |
| Education | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,373.65 | 2019-2025 | Calquence, Lynparza |
| Amgen INC. | $399.56 | 2019-2023 | Kyprolis |
| Pfizer INC. | $292.98 | 2021-2025 | |
| Tempus Ai, INC | $261.59 | 2024-2025 | Xt Cdx |
| Janssen Biotech, INC. | $235.52 | 2020-2024 | Rybrevant |
| Novartis Pharmaceuticals Corporation | $210.87 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $210.26 | 2019-2025 | Opdivo |
| Daiichi Sankyo INC. | $195.18 | 2019-2025 | Datroway |
| Alexion Pharmaceuticals, INC. | $138.45 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $126.10 | 2022-2024 | Precisetumor |
| Merck Sharp & Dohme LLC | $116.93 | 2019-2023 | Keytruda |
| Incyte Corporation | $106.82 | 2025 | Pemazyre, Monjuvi |
| Seagen INC. | $105.51 | 2022 | |
| Genzyme Corporation | $101.76 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $91.21 | 2020-2025 | Gavreto, Tavalisse, Rezlidhia |
| Eisai INC. | $64.94 | 2022-2024 | |
| Array Biopharma INC | $51.82 | 2025 | Braftovi, Mektovi, Tukysa |
| Biocon Biologics INC | $47.42 | 2025 | Ogivri |
| Genentech USA, INC. | $46.30 | 2022-2025 | Polivy |
| Abiomed | $44.09 | 2023 | Impella |
| Sobi, INC | $29.62 | 2024 | |
| Pharmaessentia USA Corporation | $29.03 | 2025 | Besremi |
| Ipsen Biopharmaceuticals, INC | $28.47 | 2025 | Onivyde |
| Beone Medicines USA, INC. | $23.42 | 2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $19.36 | 2025 | |
| Abbvie INC. | $18.64 | 2023 | |
| Lilly USA, LLC | $18.10 | 2025 | Verzenio |
| Celgene Corporation | $16.35 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.03 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prathima Prodduturi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.